LQDA
NASDAQ
US
Liquidia Corporation - Common Stock
$37,68
▲ +$0,21
(+0,56%)
Vol. 786K
6
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$3.0B
ROE
-296,8%
Margine
-176,0%
D/E
872,92
Beta
0,47
52W
$11–$36
Consenso Wall Street
15 analisti · Apr 20266
Acquisto forte
7
Compra
1
Mantieni
0
Vendi
1
Vendita forte
86,7%
Rating Compra
Grafico dei Prezzi
Titoli simili
AMRX
Amneal Pharmaceuticals Inc
P/E 671,4
$4.0B
CRNX
Crinetics Pharmaceuticals Inc
$4.4B
INDV
Indivior Pharmaceuticals, Inc
P/E 35,8
$4.5B
GPCR
Structure Therapeutics Inc
$4.2B
EWTX
Edgewise Therapeutics Inc
$2.6B
TARS
Tarsus Pharmaceuticals Inc
$3.5B
SUPN
Supernus Pharmaceuticals Inc
$2.8B
ALMS
Alumis Inc
$1.0B
AMRX
Amneal Pharmaceuticals Inc
P/E 671,4
$4.0B
Utili
Tasso di battuta: 25,0%
Prossimo report
Mag 06, 2026
Stima EPS: $0,36
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $0,36 | — | — |
| Dic 2025 | $0,18 | $0,17 | $-0,01 |
| Set 2025 | $-0,41 | $-0,04 | +$0,37 |
| Giu 2025 | $-0,44 | $-0,49 | $-0,05 |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -223.9% | -223.9% | -223.9% | -223.9% | -296.8% | -296.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -470.5% | -732.2% | -732.2% | -732.2% | -176.0% | -176.0% |
| Gross Margin | 83.1% | 69.3% | 69.3% | 69.3% | 89.1% | 89.1% |
| D/E Ratio | 1274.67 | 1274.67 | 1274.67 | 1274.67 | 872.92 | 872.92 |
| Current Ratio | 2.49 | 2.49 | 2.49 | 2.49 | 2.20 | 2.20 |
Rapporti chiave
ROA (TTM)
-49,2%
P/S (TTM)
43,35
P/B
12,9
EPS (TTM)
$-1,43
CF/Share
$-0,86
Crescita ricavi 3A
+2,9%
52W High
$36,41
52W Low
$11,26
$11,26
Intervallo 52 settimane
$36,41
Як LQDA виглядає на тлі конкурентів у Pharmaceuticals?
Група порівняння: Mid-cap Pharmaceuticals ($2B+) · 25 компаній
Оцінка LQDA vs аналоги Pharmaceuticals
P/E
—
▼
0%
sotto
peer
(30,7)
vs Peer
vs Settore
Valore equo
P/S
43,4
▲
545%
sopra
peer
(6,7)
vs Peer
vs Settore
Sopravvalutato
P/B
12,9
▲
148%
sopra
peer
(5,2)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(3,1%)
vs Peer
vs Settore
Rendimento basso
Прибутковість LQDA vs аналоги Pharmaceuticals
ROE
-296,8%
▼
1038%
sotto
peer
(-26,1%)
vs Peer
vs Settore
Debole
Net margin
-176,0%
▼
12041%
sotto
peer
(-1,5%)
vs Peer
vs Settore
Debole
Валова маржа
89,1%
▲
0%
sopra
peer
(88,9%)
vs Peer
vs Settore
Debole
ROA
-49,2%
▼
420%
sotto
peer
(-9,5%)
vs Peer
vs Settore
Debole
Фінансове здоровʼя LQDA vs аналоги Pharmaceuticals
D/E ratio
872,9
▲
3092%
sopra
peer
(27,4)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
2,2
▼
37%
sotto
peer
(3,5)
vs Peer
vs Settore
Liquidità bassa
Beta
0,5
▼
20%
sotto
peer
(0,6)
vs Peer
vs Settore
Più volatile
Радар фундаменталів LQDA
LQDA
Mediana peer
Industria
LQDA прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio